Fogari R, Zoppi A, Corradi L, Preti P, Malalamani G D, Mugellini A
Department of Internal Medicine and Therapeutics, Clinica Medica I (IRCCS), Policlinico S. Matteo, University of Pavia, Italy.
J Hypertens. 2000 Dec;18(12):1871-5. doi: 10.1097/00004872-200018120-00023.
The aim of this study was to compare the chronic effects of four dihydropyridine calcium antagonists with different pharmacologic characteristics, amlodipine, felodipine, lacidipine and manidipine,on blood pressure (BP), heart rate (HR) and plasma norepinephrine (NE) levels in patients with mild to moderate essential hypertension.
After a 4-week placebo period, 60 patients of both sexes were randomly administered amlodipine 5-10 mg once daily (o.d.) (n = 15); felodipine 5-10 mg o.d. (n = 15); lacidipine 4-6 mg o.d. (n = 15); manidipine 10-20 mg o.d. (n = 15), for 24 weeks, according to a double blind, parallel group design. Initially, for the first 2 weeks, the lowest dose of each drug was used, then higher doses were administered if sitting diastolic blood pressure (DBP) was > 90 mmHg. BP, HR and plasma NE were evaluated at the end of the placebo and active treatment periods. NE was assessed at trough, at peak and after 12 h from drug ingestion.
Administration of all four drugs reduced clinic BP to the same level after 24 weeks, whereas HR increased only with felodipine (+ 3.1 bpm; P< 0.05). Significant increases in plasma NE levels were observed after chronic therapy with amlodipine and felodipine (+ 34.9 and + 39.4% respectively; P< 0.01 versus placebo) but not with lacidipine (+ 7.1%, NS) and manidipine (+ 2.9%, NS).
These findings suggest that sympathetic activation occurred during chronic treatment with amlodipine and felodipine, whereas manidipine and lacidipine did not increase plasma noradrenaline at the times measured. The reasons for this difference are unclear; they could be related to the different pharmacological characteristic of the two drugs, lacidipine and manidipine.
本研究旨在比较四种具有不同药理特性的二氢吡啶类钙拮抗剂,即氨氯地平、非洛地平、拉西地平和马尼地平,对轻至中度原发性高血压患者血压(BP)、心率(HR)和血浆去甲肾上腺素(NE)水平的慢性影响。
经过4周的安慰剂期后,按照双盲、平行组设计,将60名男女患者随机分为四组,分别每日一次口服氨氯地平5 - 10mg(n = 15);非洛地平5 - 10mg(n = 15);拉西地平4 - 6mg(n = 15);马尼地平10 - 20mg(n = 15),治疗24周。最初,在前2周使用每种药物的最低剂量,若坐位舒张压(DBP)> 90mmHg,则给予更高剂量。在安慰剂期和积极治疗期结束时评估BP、HR和血浆NE。在药物摄入后的谷值、峰值和12小时后评估NE。
24周后,所有四种药物均将诊室血压降低至相同水平,而仅非洛地平使心率增加(+ 3.1次/分钟;P < 0.05)。氨氯地平和非洛地平长期治疗后血浆NE水平显著升高(分别为+ 34.9%和+ 39.4%;与安慰剂相比P < 0.01),而拉西地平(+ 7.1%,无统计学意义)和马尼地平(+ 2.9%,无统计学意义)则未升高。
这些发现表明,氨氯地平和非洛地平长期治疗期间发生了交感神经激活,而马尼地平和拉西地平在所测时间未增加血浆去甲肾上腺素。这种差异的原因尚不清楚;可能与拉西地平和马尼地平这两种药物的不同药理特性有关。